- Home
- RNAC
as 02-21-2025 4:00pm EST
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREDERICK |
| Market Cap: | 496.8M | IPO Year: | 2016 |
| Target Price: | $41.67 | AVG Volume (30 days): | 57.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -23.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.67 - $41.87 | Next Earning Date: | 03-06-2025 |
| Revenue: | $47,938,000 | Revenue Growth: | -62.40% |
| Revenue Growth (this year): | 56.02% | Revenue Growth (next year): | -86.17% |
Stock Insider Trading Activity of Cartesian Therapeutics Inc. (RNAC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Jan 13 '25 | Buy | $17.55 | 20,967 | $366,353.71 | 8,527,440 | |
| English Emily | RNAC | Chief Operations Officer | Jan 3 '25 | Sell | $16.78 | 1,797 | $30,149.19 | 41,132 | |
| Kurtoglu Metin | RNAC | Chief Technology Officer | Jan 3 '25 | Sell | $16.78 | 4,875 | $81,790.38 | 64,716 | |
| Davis Blaine | RNAC | Chief Financial Officer | Jan 3 '25 | Sell | $16.78 | 7,989 | $134,035.55 | 98,839 | |
| Jewell Christopher M | RNAC | Chief Scientific Officer | Jan 3 '25 | Sell | $16.78 | 2,550 | $42,782.69 | 54,776 | |
| Miljkovic Milos | RNAC | Chief Medical Officer | Jan 3 '25 | Sell | $16.78 | 1,880 | $31,541.74 | 36,341 | |
| Brunn Carsten | RNAC | President and CEO | Jan 3 '25 | Sell | $16.78 | 17,271 | $289,764.43 | 212,804 | |
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Dec 19 '24 | Buy | $18.52 | 52,189 | $965,020.79 | 8,527,440 | |
| Kurtoglu Metin | RNAC | Chief Technology Officer | Dec 9 '24 | Sell | $25.15 | 13,664 | $345,133.86 | 64,716 |
Latest Cartesian Therapeutics Inc. News
RNAC Breaking Stock News: Dive into RNAC Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
16 days ago
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewswire
a month ago
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 01/16/2025
GlobeNewswire
a month ago
Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases
GlobeNewswire
a month ago
Cartesian Therapeutics Announces New Employment Inducement Grants
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 12/27/2024
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 12/26/2024
Compare RNAC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNAC Cartesian Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.